Aldrin
CASRN 309-00-2
- IRIS Summary (PDF) (14 pp, 121 K)
- Status: Aldrin is not being reassessed by IRIS at this time.
Health Hazard Assessments for Effects Other than Cancer
Reference Dose for Oral Exposure (RfD) (PDF) (14 pp, 121 K)
last updated: 03/31/1987
|
Reference Concentration for Inhalation Exposure (RfC) (PDF) (14 pp, 121 K)
Not assessed under the IRIS Program.
Cancer Assessment
Weight of Evidence for Cancer (PDF) (14 pp, 121 K)
last updated: 09/30/1987
| WOE Characterization | Framework for WOE Characterization |
|---|---|
| B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (US EPA, 1986) |
- Orally administered aldrin produced significant increases in tumor responses in three different strains of mice in both males and females. Tumor induction has been observed for structurally related chemicals, including dieldrin, a metabolite.
- This may be a synopsis of the full weight-of-evidence narrative.
Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (14 pp, 121 K)
Oral Slope Factor:
1.7 x10 1 per mg/kg-day
Drinking Water Unit Risk:
4.9 x10 -4 per µg/L
Extrapolation Method:
Linearized multistage procedure, extra risk
Tumor site(s): Hepatic
Tumor type(s): Liver carcinoma (Davis, 1965, NCI, 1978)
Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (14 pp, 121 K)
Inhalation Unit Risk:
4.9 x10 -3 per µg/m3
Extrapolation Method:
Linearized multistage procedure, extra risk
Tumor site(s): Hepatic
Tumor type(s): Liver carcinoma (Davis, 1965, NCI, 1978)
You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.
